Heron Therapeutics Stock Price, News & Analysis (NASDAQ:HRTX)

$23.45 0.25 (1.08 %)
(As of 01/23/2018 12:57 PM ET)
Previous Close$23.20
Today's Range$23.17 - $23.90
52-Week Range$12.25 - $23.90
Volume1.42 million shs
Average Volume1.14 million shs
Market Capitalization$1.27 billion
P/E Ratio-6.19
Dividend YieldN/A
Beta2.12

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:HRTX
CUSIPN/A
Phone+1-650-3662626

Debt

Debt-to-Equity Ratio0.62%
Current Ratio2.12%
Quick Ratio2.02%

Price-To-Earnings

Trailing P/E Ratio-6.18733509234828
Forward P/E Ratio-6.94
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.28 million
Price / Sales1,183.49
Cash FlowN/A
Price / CashN/A
Book Value($0.41) per share
Price / Book-57.20

Profitability

Trailing EPS($3.79)
Net Income$-173,140,000.00
Net Margins-831.89%
Return on Equity-385.11%
Return on Assets-141.39%

Miscellaneous

Employees139
Outstanding Shares64,600,000

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.10. The biotechnology company earned $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. View Heron Therapeutics' Earnings History.

Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2018?

10 Wall Street analysts have issued 1 year price objectives for Heron Therapeutics' stock. Their forecasts range from $22.00 to $40.00. On average, they expect Heron Therapeutics' share price to reach $29.90 in the next year. View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "Late Friday, Jan. 12, Tesaro (Not Covered) announced that it had modified the Warnings section of the package insert for Varubi to include post-marketing reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions, some requiring hospitalization." (1/15/2018)
  • 2. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/10/2018)
  • 3. Mizuho analysts commented, "We analyze in greater detail Heron Therapeutics’ product HTX-011 to better understand the benefits of this extended-release combination of bupivacaine and anti-inflammatory agent meloxicam. Local anesthetics appear to lose efficacy when used in an acidic environment produced by inflammation whereas HTX-011 addresses the issue by the use of an anti-inflammation agent. We see significant upside potential if HTX-011 phase 3 readouts are positive. KeyPoints Inflammation is an unmet issue in local anesthetics. Local anesthetic failure has been observed when associated with inflammation. On page 2 and 3, we discuss two research publications to explain how inflammation can affect local anesthetics. Two theories are summarized by the authors providing evidence of reduced efficacy in generic bupivacaine when used by itself. Specifically, bupivacaine loses efficacy when used in an acidic environment produced by inflammation." (12/8/2017)
  • 4. Cowen Inc analysts commented, "Earlier today Heron stock dropped as much as 8.5% on seemingly no news." (5/26/2017)
  • 5. Needham & Company LLC analysts commented, "We initiate coverage of Heron Therapeutics, a commercial-stage specialty biopharma focused on novel extended-release injectables, at Buy with a $28 PT. HRTX made the transition to a commercial co. in 4Q16 with the launch of Sustol for CINV. Cinvanti, on file with FDA (likely 4Q17 PDUFA), will round out the CINV franchise. The main value driver, HTX-011, is an extended-release combination of bupivacaine/meloxicam in development for post-op pain management. HTX-011 successfully completed a comprehensive ph 2 program in various surgical procedures demonstrating superior efficacy to placebo and bupivacaine. HTX-011 will begin ph 3 development in 2017. Our valuation looks at the differentiated CINV assets and cash balance (~$215MM) as a floor value for HRTX, while the potential of HTX-011 remains mostly undervalued." (2/27/2017)

Are investors shorting Heron Therapeutics?

Heron Therapeutics saw a drop in short interest in December. As of December 15th, there was short interest totalling 8,395,146 shares, a drop of 16.8% from the November 30th total of 10,089,227 shares. Based on an average daily volume of 1,331,598 shares, the short-interest ratio is currently 6.3 days. Currently, 15.5% of the company's shares are sold short.

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:

  • Kevin C. Tang, Independent Chairman of the Board (Age 50)
  • Robert Harvey Rosen, President, Director (Age 61)
  • Barry D. Quart Pharm.D., Chief Executive Officer, Director (Age 60)
  • Robert E. Hoffman, Chief Financial Officer, Senior Vice President - Finance (Age 51)
  • Kimberly J. Manhard, Executive Vice President - Drug Development
  • David L. Szekeres, Senior Vice President, General Counsel, Business Development, Corporate Secretary (Age 43)
  • Thomas B. Ottoboni Ph.D., Senior Vice President - Pharmaceutical and Preclinical Research and Development (Age 58)
  • Sean T. Ristine, Vice President - Human Resources (Age 47)
  • Christian Waage, Director (Age 50)
  • Craig A. Johnson, Independent Director (Age 56)

Who owns Heron Therapeutics stock?

Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.38%), Private Asset Management Inc. (0.14%) and Fox Run Management L.L.C. (0.03%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?

Heron Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Private Asset Management Inc. and Fox Run Management L.L.C.. View Insider Buying and Selling for Heron Therapeutics.

How do I buy Heron Therapeutics stock?

Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of Heron Therapeutics stock can currently be purchased for approximately $23.45.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.27 billion and generates $1.28 million in revenue each year. The biotechnology company earns $-173,140,000.00 in net income (profit) each year or ($3.79) on an earnings per share basis. Heron Therapeutics employs 139 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 Campus Point Ct Ste 200, SAN DIEGO, CA 92121-1513, United States. The biotechnology company can be reached via phone at +1-650-3662626 or via email at [email protected]


MarketBeat Community Rating for Heron Therapeutics (HRTX)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Heron Therapeutics (NASDAQ:HRTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.90$29.80$30.11$33.13
Price Target Upside: 38.43% upside89.81% upside94.27% upside104.48% upside

Heron Therapeutics (NASDAQ:HRTX) Consensus Price Target History

Price Target History for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018MizuhoReiterated RatingBuy$28.00LowView Rating Details
1/15/2018Cantor FitzgeraldSet Price TargetBuy$31.00LowView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$22.00HighView Rating Details
12/14/2017OppenheimerSet Price TargetBuy$27.00LowView Rating Details
12/6/2017CowenReiterated RatingBuy$40.00MediumView Rating Details
11/12/2017Noble FinancialReiterated RatingBuyN/AView Rating Details
9/27/2017Northland SecuritiesInitiated CoverageOutperform -> Outperform$40.00LowView Rating Details
8/16/2017Jefferies GroupReiterated RatingBuyLowView Rating Details
7/18/2017AegisReiterated RatingBuy$33.00LowView Rating Details
2/27/2017Needham & Company LLCInitiated CoverageBuy -> Buy$28.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$45.00N/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Heron Therapeutics (NASDAQ:HRTX) Earnings History and Estimates Chart

Earnings by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ HRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.87)($0.77)$8.12 million$8.57 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.90)($0.80)$4.53 million$8.51 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.94)($1.00)$1.96 million$3.63 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.17)($1.22)$1.07 million$1.28 millionViewN/AView Earnings Details
11/8/2016Q3 2016($1.17)($1.24)ViewN/AView Earnings Details
8/8/2016Q2($0.96)($1.17)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.64)($0.70)ViewN/AView Earnings Details
3/13/2015Q4 2014($0.69)($0.71)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014Q2 2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.58)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.80)($0.80)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.80)($1.00)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.60)($0.80)ViewN/AView Earnings Details
3/1/2013Q4 2012($0.40)($0.60)ViewN/AView Earnings Details
11/5/2012Q3 2012($0.20)($0.40)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.40)($0.40)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.40)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.42)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.94)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.66)ViewN/AView Earnings Details
3/28/2011Q4 2010($0.76)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.82)ViewN/AView Earnings Details
8/16/2010Q2 2010($1.88)ViewN/AView Earnings Details
5/17/2010Q1 2010($1.46)ViewN/AView Earnings Details
3/15/2010Q4 2009($1.22)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.80)ViewN/AView Earnings Details
8/4/2009Q2 2009($2.54)ViewN/AView Earnings Details
5/14/2009Q1 2009($2.00)($1.92)ViewN/AView Earnings Details
3/31/2009Q4 2008($4.00)($2.50)ViewN/AView Earnings Details
11/5/2008Q3 2008($4.40)($4.02)ViewN/AView Earnings Details
8/14/2008Q2 2008($3.98)ViewN/AView Earnings Details
5/15/2008Q1 2008($4.44)ViewN/AView Earnings Details
3/13/2008Q4 2007($3.80)($5.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Heron Therapeutics (NASDAQ:HRTX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.72)($0.64)($0.68)
Q2 20182($0.67)($0.61)($0.64)
Q3 20182($0.59)($0.46)($0.53)
Q4 20182($0.45)($0.42)($0.44)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Heron Therapeutics (NASDAQ:HRTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Heron Therapeutics (NASDAQ HRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.93%
Institutional Ownership Percentage: 98.21%
Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ HRTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018Kimberly ManhardVPSell7,584$20.00$151,680.007,584View SEC Filing  
4/24/2017Kimberly ManhardVPSell21,542$15.33$330,238.865,250View SEC Filing  
1/19/2017Kevin C TangDirectorBuy2,459,016$12.20$29,999,995.20View SEC Filing  
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00102,640View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00178,968View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Heron Therapeutics (NASDAQ HRTX) News Headlines

Source:
DateHeadline
Options Traders Expect Huge Moves in Heron Therapeutics (HRTX) StockOptions Traders Expect Huge Moves in Heron Therapeutics (HRTX) Stock
www.zacks.com - January 22 at 8:29 AM
BidaskClub Upgrades Heron Therapeutics (HRTX) to BuyBidaskClub Upgrades Heron Therapeutics (HRTX) to Buy
www.americanbankingnews.com - January 20 at 9:48 AM
Heron Therapeutics Inc (HRTX) Given Average Recommendation of "Buy" by BrokeragesHeron Therapeutics Inc (HRTX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 19 at 7:36 PM
Cantor Fitzgerald Reaffirms Buy Rating for Heron Therapeutics (HRTX)Cantor Fitzgerald Reaffirms Buy Rating for Heron Therapeutics (HRTX)
www.americanbankingnews.com - January 15 at 8:56 PM
Kimberly Manhard Sells 7,584 Shares of Heron Therapeutics Inc (HRTX) StockKimberly Manhard Sells 7,584 Shares of Heron Therapeutics Inc (HRTX) Stock
www.americanbankingnews.com - January 12 at 6:58 PM
Heron Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90Heron Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
finance.yahoo.com - January 11 at 3:25 PM
Heron Therapeutics Inc Forecasted to Post FY2017 Earnings of ($3.40) Per Share (HRTX)Heron Therapeutics Inc Forecasted to Post FY2017 Earnings of ($3.40) Per Share (HRTX)
www.americanbankingnews.com - January 10 at 6:56 AM
Analyzing Heron Therapeutics (HRTX) & Icon (ICLR)Analyzing Heron Therapeutics (HRTX) & Icon (ICLR)
www.americanbankingnews.com - January 9 at 8:00 AM
Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises - Business Wire (press release)Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises - Business Wire (press release)
www.businesswire.com - January 8 at 3:28 PM
Heron Therapeutics Highlights Progress in CINV and Pain Management FranchisesHeron Therapeutics Highlights Progress in CINV and Pain Management Franchises
finance.yahoo.com - January 8 at 11:09 AM
Heron Therapeutics Sees Unusually High Options Volume (HRTX)Heron Therapeutics Sees Unusually High Options Volume (HRTX)
www.americanbankingnews.com - January 7 at 2:40 AM
Cantor Fitzgerald Reiterates $31.00 Price Target for Heron Therapeutics (HRTX)Cantor Fitzgerald Reiterates $31.00 Price Target for Heron Therapeutics (HRTX)
www.americanbankingnews.com - January 6 at 9:56 AM
Heron Therapeutics Inc to Post FY2022 Earnings of $4.53 Per Share, Leerink Swann Forecasts (HRTX)Heron Therapeutics Inc to Post FY2022 Earnings of $4.53 Per Share, Leerink Swann Forecasts (HRTX)
www.americanbankingnews.com - January 5 at 8:40 PM
Heron Therapeutics Inc (HRTX) Forecasted to Post Q4 2017 Earnings of ($0.76) Per ShareHeron Therapeutics Inc (HRTX) Forecasted to Post Q4 2017 Earnings of ($0.76) Per Share
www.americanbankingnews.com - January 5 at 9:40 AM
$7.98 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter$7.98 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter
www.americanbankingnews.com - January 4 at 6:28 PM
Heron: Strong Position With Product Launch Upcoming - Seeking AlphaHeron: Strong Position With Product Launch Upcoming - Seeking Alpha
seekingalpha.com - January 4 at 8:02 AM
Heron Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceHeron Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 8:31 PM
Heron Therapeutics (HRTX) Now Covered by Leerink SwannHeron Therapeutics (HRTX) Now Covered by Leerink Swann
www.americanbankingnews.com - January 2 at 5:18 PM
Want To Invest In Heron Therapeutics Inc (NASDAQ:HRTX)? Here’s How It Performed LatelyWant To Invest In Heron Therapeutics Inc (NASDAQ:HRTX)? Here’s How It Performed Lately
finance.yahoo.com - January 2 at 8:16 AM
Heron Therapeutics (HRTX) Upgraded at ValuEngineHeron Therapeutics (HRTX) Upgraded at ValuEngine
www.americanbankingnews.com - January 1 at 10:28 PM
Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid ... - Seeking AlphaYour Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid ... - Seeking Alpha
seekingalpha.com - December 30 at 8:26 AM
Heron Therapeutics Inc (HRTX) Short Interest UpdateHeron Therapeutics Inc (HRTX) Short Interest Update
www.americanbankingnews.com - December 30 at 2:34 AM
Heron Therapeutics Inc (HRTX) Given Consensus Recommendation of "Buy" by AnalystsHeron Therapeutics Inc (HRTX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 25 at 6:30 PM
FY2020 EPS Estimates for Heron Therapeutics Inc Lifted by Jefferies Group (HRTX)FY2020 EPS Estimates for Heron Therapeutics Inc Lifted by Jefferies Group (HRTX)
www.americanbankingnews.com - December 25 at 5:10 PM
Heron Therapeutics (HRTX) Rating Increased to Hold at BidaskClubHeron Therapeutics (HRTX) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - December 24 at 8:15 AM
Heron Therapeutics Earns Relative Strength Rating Upgrade; Hits Key BenchmarkHeron Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Benchmark
finance.yahoo.com - December 20 at 3:23 PM
Heron Therapeutics, Inc. is trading above its 50 day moving average : HRTX-US : December 20, 2017Heron Therapeutics, Inc. is trading above its 50 day moving average : HRTX-US : December 20, 2017
finance.yahoo.com - December 20 at 7:47 AM
Research Analysts Offer Predictions for Heron Therapeutics Incs FY2017 Earnings (HRTX)Research Analysts Offer Predictions for Heron Therapeutics Inc's FY2017 Earnings (HRTX)
www.americanbankingnews.com - December 18 at 2:30 AM
Oppenheimer Weighs in on Heron Therapeutics Incs FY2020 Earnings (HRTX)Oppenheimer Weighs in on Heron Therapeutics Inc's FY2020 Earnings (HRTX)
www.americanbankingnews.com - December 15 at 11:24 PM
Oppenheimer Analysts Give Heron Therapeutics (HRTX) a $27.00 Price TargetOppenheimer Analysts Give Heron Therapeutics (HRTX) a $27.00 Price Target
www.americanbankingnews.com - December 15 at 12:08 AM
Heron Therapeutics (HRTX) "Buy" Rating Reiterated at MizuhoHeron Therapeutics' (HRTX) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - December 9 at 12:08 PM
Investors Purchase High Volume of Call Options on Heron Therapeutics (HRTX)Investors Purchase High Volume of Call Options on Heron Therapeutics (HRTX)
www.americanbankingnews.com - December 8 at 1:32 AM
Cowen Reiterates "Buy" Rating for Heron Therapeutics (HRTX)Cowen Reiterates "Buy" Rating for Heron Therapeutics (HRTX)
www.americanbankingnews.com - December 7 at 3:38 PM
Heron Therapeutics To Take Flight In 2018 - Seeking AlphaHeron Therapeutics To Take Flight In 2018 - Seeking Alpha
seekingalpha.com - December 6 at 8:13 AM
Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : December 6, 2017Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : December 6, 2017
finance.yahoo.com - December 6 at 8:13 AM
Why Heron Therapeutics Stock Is Crashing TodayWhy Heron Therapeutics Stock Is Crashing Today
finance.yahoo.com - December 6 at 8:13 AM
After-Hours Stock Movers 12/04: (COLL) (DEPO) Higher; (ASNA) (HRTX) (HOME) Lower (more...)After-Hours Stock Movers 12/04: (COLL) (DEPO) Higher; (ASNA) (HRTX) (HOME) Lower (more...)
www.streetinsider.com - December 5 at 3:24 PM
GALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff - NasdaqGALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff - Nasdaq
www.nasdaq.com - December 5 at 7:49 AM
Heron Therapeutics (HRTX) Plans Public Offering of Common Stock - StreetInsider.comHeron Therapeutics (HRTX) Plans Public Offering of Common Stock - StreetInsider.com
www.streetinsider.com - December 5 at 7:49 AM
Heron Therapeutics Announces Public Offering of Common StockHeron Therapeutics Announces Public Offering of Common Stock
finance.yahoo.com - December 5 at 7:49 AM
Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and PfizerFree Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer
www.bizjournals.com - December 1 at 8:39 AM
Heron Therapeutics (HRTX) Upgraded to "Hold" by ValuEngineHeron Therapeutics (HRTX) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - November 30 at 10:28 PM
Heron Therapeutics, Inc. (HRTX) Given Consensus Recommendation of "Buy" by AnalystsHeron Therapeutics, Inc. (HRTX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 30 at 7:46 PM
$7.98 Million in Sales Expected for Heron Therapeutics, Inc. (HRTX) This Quarter$7.98 Million in Sales Expected for Heron Therapeutics, Inc. (HRTX) This Quarter
www.americanbankingnews.com - November 30 at 4:34 PM
 Brokerages Expect Heron Therapeutics, Inc. (HRTX) to Announce -$0.83 EPS Brokerages Expect Heron Therapeutics, Inc. (HRTX) to Announce -$0.83 EPS
www.americanbankingnews.com - November 28 at 3:27 AM
What does Heron Therapeutics Incs (HRTX) Balance Sheet Tell Us Abouts Its Future? - Yahoo FinanceWhat does Heron Therapeutics Inc's (HRTX) Balance Sheet Tell Us Abouts Its Future? - Yahoo Finance
finance.yahoo.com - November 23 at 4:49 PM
Heron Therapeutics, Inc. (HRTX) Lifted to Buy at Zacks Investment ResearchHeron Therapeutics, Inc. (HRTX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 23 at 12:46 AM
What does Heron Therapeutics Inc’s (HRTX) Balance Sheet Tell Us Abouts Its Future?What does Heron Therapeutics Inc’s (HRTX) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - November 21 at 7:39 PM
Heron Therapeutics: Wait For A Dip Before Jumping In - Seeking AlphaHeron Therapeutics: Wait For A Dip Before Jumping In - Seeking Alpha
seekingalpha.com - November 18 at 6:44 PM
Heron Therapeutics (HRTX) Presents At Jefferies 2017 London Healthcare Conference - SlideshowHeron Therapeutics (HRTX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 2:18 PM

SEC Filings

Heron Therapeutics (NASDAQ:HRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Heron Therapeutics (NASDAQ:HRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Heron Therapeutics (NASDAQ HRTX) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.